AU753657B2 - Combination therapy for reducing the risks associated with cardio-and cerebrovascular disease - Google Patents

Combination therapy for reducing the risks associated with cardio-and cerebrovascular disease Download PDF

Info

Publication number
AU753657B2
AU753657B2 AU13612/99A AU1361299A AU753657B2 AU 753657 B2 AU753657 B2 AU 753657B2 AU 13612/99 A AU13612/99 A AU 13612/99A AU 1361299 A AU1361299 A AU 1361299A AU 753657 B2 AU753657 B2 AU 753657B2
Authority
AU
Australia
Prior art keywords
phenyl
methylsulfonyl
inhibitor
furan
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU13612/99A
Other languages
English (en)
Other versions
AU1361299A (en
Inventor
Melvin Winokur
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9806688.9A external-priority patent/GB9806688D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of AU1361299A publication Critical patent/AU1361299A/en
Application granted granted Critical
Publication of AU753657B2 publication Critical patent/AU753657B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
AU13612/99A 1997-10-22 1998-10-16 Combination therapy for reducing the risks associated with cardio-and cerebrovascular disease Ceased AU753657B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US6269197P 1997-10-22 1997-10-22
US60/062691 1997-10-22
GBGB9806688.9A GB9806688D0 (en) 1998-03-27 1998-03-27 Combination therapy for reducing the risks associated with cardio-and cerebrovascular diease
GB9806688 1998-03-27
PCT/US1998/021901 WO1999020110A1 (en) 1997-10-22 1998-10-16 Combination therapy for reducing the risks associated with cardio- and cerebrovascular disease

Publications (2)

Publication Number Publication Date
AU1361299A AU1361299A (en) 1999-05-10
AU753657B2 true AU753657B2 (en) 2002-10-24

Family

ID=26313383

Family Applications (1)

Application Number Title Priority Date Filing Date
AU13612/99A Ceased AU753657B2 (en) 1997-10-22 1998-10-16 Combination therapy for reducing the risks associated with cardio-and cerebrovascular disease

Country Status (5)

Country Link
EP (1) EP1024696A4 (ja)
JP (1) JP2001520174A (ja)
AU (1) AU753657B2 (ja)
CA (1) CA2306646A1 (ja)
WO (1) WO1999020110A1 (ja)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184248B1 (en) * 1996-09-05 2001-02-06 Robert K. K. Lee Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
EP1197228A4 (en) * 1999-07-02 2004-03-10 Hisamitsu Pharmaceutical Co DRUG COMPOSITIONS FOR THE TREATMENT OF COLORECTAL CANCER
WO2001056596A1 (en) 2000-02-04 2001-08-09 Children's Hospital Research Foundation Use of lysosomal acid lipase for treating atherosclerosis and related diseases
GB2361185A (en) * 2000-04-10 2001-10-17 Nicholas J Wald Pharmaceutical formulation for the prevention of cardiovascular disease
DK1303265T3 (da) 2000-07-20 2007-11-12 Lauras As Anvendelse af COX-2-inhibitorer, som immunostimulerende midler ved behandling af HIV eller AIDS
WO2002028270A2 (en) * 2000-10-06 2002-04-11 Probiochem, Llc The treatment of cancer utilizing a cox-2 inhibitor and a hmg-coa reductase inhibitor
US6534540B2 (en) 2000-10-06 2003-03-18 George Kindness Combination and method of treatment of cancer utilizing a COX-2 inhibitor and a 3-hydroxy-3-methylglutaryl-coenzyme-a (HMG-CoA) reductase inhibitor
WO2002094021A1 (en) * 2000-10-06 2002-11-28 Probiochem, Llc A combination and method of treatment of cancer utilizing a cox-2 inhibitor and an hmg-coa inhibitor and cystine to enhance glutathione
EP1406609B1 (en) 2000-12-21 2006-09-06 Nitromed, Inc. Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use
JP4611622B2 (ja) * 2002-07-11 2011-01-12 第一三共株式会社 血中脂質改善又は血中ホモシステイン低下のための医薬組成物
WO2004006919A1 (ja) * 2002-07-11 2004-01-22 Sankyo Company, Limited 血中脂質改善又は血中ホモシステイン低下のための医薬組成物
EP1982711A1 (en) 2005-05-31 2008-10-22 Mylan Laboratories, Inc Compositions comprsing nebivolol
US20070037797A1 (en) * 2005-08-15 2007-02-15 Hellstrom Harold R Method of reducing the risk of adverse cardiovascular (CV) events associated with the administration of pharmaceutical agents which favor CV events
CA2627599A1 (en) * 2005-11-08 2007-05-18 Ranbaxy Laboratories Limited Process for (3r,5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxy methyl phenyl amino)carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid hemi calcium salt
US8404275B2 (en) * 2007-07-01 2013-03-26 Vitalis Llc Combination tablet with chewable outer layer
CN104105478A (zh) 2011-10-28 2014-10-15 维塔利斯公司 抗发红组合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL112639A0 (en) * 1994-03-11 1995-05-26 Bristol Myers Squibb Co A pharmaceutical composition containing pravastin
AU6274896A (en) * 1995-06-06 1996-12-24 Procyte Corporation Stable copper(i) complexes as active therapeutic substances
AU2063397A (en) * 1996-03-05 1997-09-22 Children's Hospital Medical Center Mercapto derivatives as inhibitors of cyclooxygenases

Also Published As

Publication number Publication date
EP1024696A4 (en) 2004-07-14
CA2306646A1 (en) 1999-04-29
WO1999020110A1 (en) 1999-04-29
AU1361299A (en) 1999-05-10
JP2001520174A (ja) 2001-10-30
EP1024696A1 (en) 2000-08-09

Similar Documents

Publication Publication Date Title
US6245797B1 (en) Combination therapy for reducing the risks associated with cardio-and-cerebrovascular disease
AU753657B2 (en) Combination therapy for reducing the risks associated with cardio-and cerebrovascular disease
US6136804A (en) Combination therapy for treating, preventing, or reducing the risks associated with acute coronary ischemic syndrome and related conditions
US6232315B1 (en) Method for treating inflammatory diseases by administering a thrombin inhibitor
KR100373622B1 (ko) 사이클로옥시게나제-2로매개된질환의1일1회치료용조성물
CA2251972A1 (en) Combination therapy for reducing the risks associated with cardiovascular disease
US6673831B1 (en) Combination therapy for reducing the risks associated with cardiovascular disease
CA2321687C (en) Combination of a selective nmda nr2b antagonist and a cox-2 inhibitor
CA2407469A1 (en) Combination therapy using cox-2 selective inhibitor and thromboxane inhibitor and compositions therefor
US20020115689A1 (en) Combination therapy for treating neurodegenerative disease
CA2322824A1 (en) Combination therapy and composition for acute coronary ischemic syndrome and related conditions
WO2001022962A1 (en) Anti-hypercholesterolemic drug combination
EP2686429A1 (en) Compositions, process of preparation of said compositions and method of treating inflammatory diseases
WO2003094924A1 (en) Combination therapy for treating cyclooxygenase-2 mediated diseases in patients at risk of thrombotic cardiovascular events
US6890941B1 (en) Compositions containing HMG Co-A reductase inhibitors and policosanol
WO2003039542A1 (en) Combination therapy for treating alzheimer's disease
KR20050025604A (ko) 동맥 경화증 치료를 위한 의약 조성물
US20060079579A1 (en) Combinations of valsartan with cox-2 inhibitors
CA2327585A1 (en) Use of a cox-2 inhibitor and a nk-1 receptor antagonist for treating inflammation
JP2004051639A (ja) 動脈硬化症治療のための医薬組成物
US20040097573A1 (en) Use of a COX-2 inhibitor and a NK-1 receptor antagonist for treating inflammation
AU715676B2 (en) Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases
US20050215611A1 (en) Combination therapy for treating cyclooxygenase-2 mediated diseases in patients at risk of thrombotic cardiovascular events

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)